IP Library Patent Application 13084734
Patent Application
App. No. 13/084,734

Compositions and Methods for Treating Collagen-Mediated Diseases

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/084,734
Abstract

A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.

Claims (33)

1 . A method of purifying collagenase I and collagenase II from Clostridium histolyticum, comprising the steps of:

a. fermenting Clostridium histolyticum to obtain a crude harvest comprising collagenase I and collagenase II;

b. subjecting the crude harvest to hydrophobic interaction chromatography (HIC) as a product capture step under conditions suitable for collagenase I and collagenase II binding to the HIC column; and

c. eluting collagenase I and II from the HIC column.

2 . The method of claim 1 , wherein ammonium sulphate is added to the crude harvest prior to the HIC product capture step and wherein the collagenase I and collagenase II are eluted with a solution containing no ammonium sulphate.

3 . The method of claim 1 , wherein the crude harvest is filtered through an anion exchange filter prior to step (b).

4 . The method of claim 1 , wherein leupeptin is added to the eluate from the HIC column.

5 . The method of claim 1 , comprising the steps of:

i) filtering the crude harvest obtained in step (a) through an anion exchange filter;

ii) adding ammonium sulphate;

iii) subjecting the harvest obtained from step (ii) to the HIC column;

v) conducting the eluting step (c) with a solution containing no ammonium sulfate;

vi) adding leupeptin to the eluate obtained from step (v); and

vii) separating collagenase I and collagenase II using ion-exchange chromatography;

vii) combining the collagenase I and collagenase II purified from step (vii) at a ratio of about 1 to 1.

6 . The method of claim 1 , wherein the purified collagenase I is at least 95% by area pure as determined by reverse phase high performance liquid chromatography.

7 . The method of claim 1 , wherein the purified collagenase II is at least 95% by area pure as determined by reverse phase high performance liquid chromatography.

8 . The method of claim 6 , wherein the purified collagenase II is at least 95% by area pure as determined by reverse phase high performance liquid chromatography.

9 . The method of claim 1 , wherein the purified collagenase I is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

10 . The method of claim 1 , wherein the purified collagenase II is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

11 . The method of claim 9 , wherein the purified collagenase II is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

12 . Isolated and purified collagenase I purified by the method of claim 1 .

13 . The isolated and purified collagenase I of claim 12 , wherein the collagenase I is at least 95% by area pure as determined by reverse phase high performance liquid chromatography.

14 . The isolated and purified collagenase I of claim 12 , wherein the collagenase I is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

15 . The isolated and purified collagenase I of claim 12 , wherein the collagenase I contains less than about 1% by area of clostripain as determined by reverse phase high performance liquid chromatography.

16 . Isolated and purified collagenase II purified by the method of claim 1 .

17 . The isolated and purified collagenase II of claim 16 , wherein the collagenase I is at least 95% by area pure as determined by reverse phase high performance liquid chromatography.

18 . The isolated and purified collagenase II of claim 16 , wherein the collagenase I is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

19 . The isolated and purified collagenase II of claim 17 , wherein the collagenase I contains less than about 1% by area of clostripain as determined by reverse phase high performance liquid chromatography.

20 . A drug product comprising isolated and purified collagenase I and collagenase II, wherein the collagenase I and collagenase II are purified according to the method of claim 1 , and wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1.

21 . A drug product comprising purified collagenase I and collagenase II, wherein the collagenase I and collagenase II are purified according to the method of claim 5 , and wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1.

22 . A drug product consisting of purified collagenase I and collagenase II, wherein the collagenase I and collagenase II are purified according to the method of claim 1 , and wherein the collagenase I and collagenase II are present at a mass ratio of about 1 to 1.

23 . A drug product consisting of purified collagenase I and collagenase II, wherein the collagenase I and collagenase II are purified according to the method of claim 5 , and wherein the collagenase I and collagenase II are present at a mass ratio of about 1 to 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2015
From: AUXILIUM US HOLDINGS, LLC
To: AUXILIUM BERMUDA UNLIMITED
Reel/Frame 035113/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2012
From: AUXILIUM US HOLDINGS, LLC
To: AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.
Reel/Frame 027722/0001 →